Global protein-expression profiling for reclassification of malignant fibrous histiocytoma

Kazutaka Kikuta, Hideo Morioka, Akira Kawai, Tadashi Kondo

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)


According to the newest World Health Organization (WHO) classification for soft tissue tumors in 2013, malignant fibrous histiocytoma (MFH) has been gone. Most sarcomas called MFH were reclassified to be high-grade pleomorphic forms of leiomyosarcoma, liposarcoma, rhabdomyosarcoma, and other sarcomas by recent molecular technologies. However, about 10% to 15% of sarcomas called MFH before, still cannot be given a precise classification, and these are now called undifferentiated pleomorphic sarcoma or are still called MFH. Further molecular approaches including proteomic approaches are imperative to classify these unclassified sarcomas for improving clinical outcomes of the patients with soft tissue sarcomas. This article is part of a Special Issue entitled: Medical Proteomics.

Original languageEnglish
Pages (from-to)696-701
Number of pages6
JournalBiochimica et Biophysica Acta - Proteins and Proteomics
Issue number6
Publication statusPublished - 2015 Jun 1


  • Classification
  • MFH
  • Proteomics
  • STS

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biophysics
  • Biochemistry
  • Molecular Biology


Dive into the research topics of 'Global protein-expression profiling for reclassification of malignant fibrous histiocytoma'. Together they form a unique fingerprint.

Cite this